Advertisement

Lower Midline Versus Pfannenstiel Incision in Pelvic Lymphadenectomy in Endometrial Cancer

  • Helmy A. RadyEmail author
  • Noha E. Mohammed
  • Mohammed H. Ragab
Original Article
  • 17 Downloads

Abstract

Objective

Is to perform pelvic lymph nodes dissection through Pfannenstiel incision in comparison with lower midline incision.

Methods

The study will include 50 women diagnosed previously as endometrial cancer patients. Patients were subdivided equally into two groups regarding abdominal incision group A lower midline incision, while group B Pfannenstiel incision. Comparison between the two groups regarding number of lymph nodes dissected, complication and operative time was made.

Results

Pelvic lymph nodes dissection through lower midline incision takes shorter time versus Pfannenstiel incision (41.6 vs. 59.8 min), more lymph nodes in midline than Pfannenstiel incisions (26.5 vs. 21 lymph nodes), and endometrioid adenocarcinoma was the commonest type.

Conclusion

Pelvic lymph nodes dissection in patients with endometrial cancer could be performed safely using lower midline incision or Pfannenstiel incision.

Keywords

Endometrial cancer Pelvic lymph nodes Pfannenstiel incision Lower midline incision 

Notes

Compliance with Ethical Standards

Conflict of interest

All authors declare that there is no conflict of interest.

References

  1. 1.
    Kikalishvili N, Beriashvili R, Muzashvili T, Burkadze G. Specificities of endometrial proliferation/stem cell index distribution in endometrioid carcinoma of different grade of malignancy. Georgian Med News. 2018;276:117–23.Google Scholar
  2. 2.
    Bogani G, Dowdy SC, Cliby WA, Ghezzi F, Rossetti D, Mariani A. Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence. J Obstet Gynaecol Res. 2014;40(2):301–11.  https://doi.org/10.1111/jog.12344.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Todo Y, Sakuragi N. Systematic lymphadenectomy in endometrial cancer. J Obstet Gynaecol Res. 2013;39:471–7.CrossRefGoogle Scholar
  4. 4.
    Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008;109:11–8.CrossRefGoogle Scholar
  5. 5.
    van de Poll-Franse LV, Pijnenborg JM, Boll D, et al. Health related quality of life and symptoms after pelvic lymphadenectomy or radiotherapy vs. no adjuvant regional treatment in early-stage endometrial carcinoma: a large population-based study. Gynecol Oncol. 2012;127:153–60.CrossRefGoogle Scholar
  6. 6.
    Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol. 2012;125:531–5.CrossRefGoogle Scholar
  7. 7.
    Kang S, Yoo HJ, Hwang JH, Lim MC, Seo SS, Park SY. Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies. Gynecol Oncol. 2011;123:522–7.CrossRefGoogle Scholar
  8. 8.
    Ballester M, Dubernard G, Lecuru F, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTIENDO). Lancet Oncol. 2011;12:469–76.CrossRefGoogle Scholar
  9. 9.
    Kim CH, Soslow RA, Park KJ, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer. 2013;23:964–70.CrossRefGoogle Scholar
  10. 10.
    Guan J, Xie L, Luo X, Yang B, Zhang H, Zhu Q, et al. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification. J Gynecol Oncol. 2019;30:e13.  https://doi.org/10.3802/jgo.2019.30.e13 (English. Published online Oct 29, 2018.CrossRefPubMedGoogle Scholar
  11. 11.
    Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125–36 (Published erratum appears in Lancet 2009; 373: 1764).CrossRefGoogle Scholar
  12. 12.
    Lin Y, Zhou J, Cao L, Xu Q, Hao J, Zhao L, et al. Serum calcium is a novel parameter to assess metabolic syndrome in endometrial carcinoma. J Gynecol Oncol. 2019;30:e12.  https://doi.org/10.3802/jgo.2019.30.e12 (English. Published online Oct 11, 2018).CrossRefPubMedGoogle Scholar
  13. 13.
    Takahash K, Yunokawa M, Sasada S, Takehara Y, Miyasaka N, Kato T, et al. A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma. J Gynecol Oncol. 2019;30:e8.  https://doi.org/10.3802/jgo.2019.30.e8 (.CrossRefGoogle Scholar
  14. 14.
    Rodrigues da Cunha Colombo Bonadio R, Gondim Meira Velame Azevedo R, Harada G, Cabral Severino da Costa S, Miranda V, de Freitas D, et al. Adjuvant carboplatin and paclitaxel chemotherapy followed by radiotherapy in high-risk endometrial cancer: a retrospective analysis. J Glob Oncol. 2018;4:1–8.  https://doi.org/10.1200/jgo.17.00146.CrossRefPubMedGoogle Scholar
  15. 15.
    Komiyama S, Takeya C, Takahashi R, Nagasaki S, Kubushiro K. Less invasive endometrial cancer surgery with extraperitoneal pelvic and para-aortic lymphadenectomy via a small midline abdominal incision and the retroperitoneal approach. J Cancer. 2016;7(8):890–9.  https://doi.org/10.7150/jca.14987.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  1. 1.Department of Obstetrics and Gynaecology, Faculty of MedicineUniversity of Alexandria, El Shatby Maternity University HospitalAlexandriaEgypt
  2. 2.Dar Ismail Maternity HospitalAlexandriaEgypt

Personalised recommendations